AM-2233: Difference between revisions
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEMBL', 'CAS_number'). |
→References: Fixed spacing between stub template and category templates. |
||
(53 intermediate revisions by 36 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
|||
⚫ | |||
| Watchedfields = changed |
|||
⚫ | |||
⚫ | |||
⚫ | |||
| image = AM-2233_structure.png |
| image = AM-2233_structure.png |
||
| width = 200 |
| width = 200 |
||
Line 11: | Line 14: | ||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
||
| legal_CA = |
| legal_CA = Schedule II |
||
| legal_DE = Anlage II |
|||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|||
| legal_UK = Class B |
|||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
||
| legal_NZ = Temporary Class |
|||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
Line 22: | Line 27: | ||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = {{cascite|changed|??}} |
|||
| CAS_number = |
| CAS_number = 444912-75-8 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = Z489688DK3 |
|||
| ATC_prefix = |
| ATC_prefix = |
||
| ATC_suffix = |
| ATC_suffix = |
||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|||
| ChEMBL = 364266 |
| ChEMBL = 364266 |
||
| PubChem = 10226340 |
| PubChem = 10226340 |
||
Line 37: | Line 46: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=22 | H=23 | I=1 | N=2 | O=1 |
| C=22 | H=23 | I=1 | N=2 | O=1 |
||
| molecular_weight = 458.334 g/mol |
|||
| smiles = Ic3ccccc3C(=O)c1cn(CC2CCCCN2C)c4c1cccc4 |
| smiles = Ic3ccccc3C(=O)c1cn(CC2CCCCN2C)c4c1cccc4 |
||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
Line 45: | Line 53: | ||
}} |
}} |
||
'''AM-2233''' is a drug |
'''AM-2233''' is a drug that acts as a highly potent [[full agonist]] for the [[cannabinoid receptor]]s, with a [[Dissociation constant|''K''<sub>i</sub>]] of 1.8 nM at [[Cannabinoid receptor 1|CB<sub>1</sub>]] and 2.2 nM at [[Cannabinoid receptor 2|CB<sub>2</sub>]] as the active (''R'') [[enantiomer]].<ref>{{Cite thesis |type=PhD Dissertation |title=Design and synthesis of selective cannabinoid receptor ligands: Aminoalkylindole and other heterocyclic analogs |author = Hongfeng Deng |year=2000 |publisher=University of Connecticut |id={{ProQuest|304624325}} }}</ref> It was developed as a selective [[isotopic labelling|radioligand]] for the cannabinoid receptors and has been used as its [[Iodine-131|<sup>131</sup>I]] derivative for mapping the distribution of the CB<sub>1</sub> receptor in the brain.<ref name="pmid16190764">{{cite journal | vauthors = Deng H, Gifford AN, Zvonok AM, Cui G, Li X, Fan P, Deschamps JR, Flippen-Anderson JL, Gatley SJ, Makriyannis A | display-authors = 6 | title = Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor | journal = Journal of Medicinal Chemistry | volume = 48 | issue = 20 | pages = 6386–6392 | date = October 2005 | pmid = 16190764 | doi = 10.1021/jm050135l }}</ref><ref>{{Cite book | vauthors = Hanuš LR, Mechoulam R | title = Cannabinoids as Therapeutics | doi = 10.1007/3-7643-7358-X_2 | pages = 23–46 | year = 2005 | chapter = Cannabinoid chemistry: an overview | series = Milestones in Drug Therapy MDT | isbn = 978-3-7643-7055-8 }}</ref><ref name="pmid16438957">{{cite journal | vauthors = Shen CP, Xiao JC, Armstrong H, Hagmann W, Fong TM | title = F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist | journal = European Journal of Pharmacology | volume = 531 | issue = 1–3 | pages = 41–46 | date = February 2006 | pmid = 16438957 | doi = 10.1016/j.ejphar.2005.12.026 }}</ref><ref>{{cite journal | vauthors = Dhawan J, Deng H, Gatley SJ, Makriyannis A, Akinfeleye T, Bruneus M, Dimaio AA, Gifford AN | display-authors = 6 | title = Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233 | journal = Synapse | volume = 60 | issue = 2 | pages = 93–101 | date = August 2006 | pmid = 16715483 | doi = 10.1002/syn.20277 | s2cid = 21269336 | author-link4 = Alexandros Makriyannis }} |
||
</ref><ref name="pmid20641836">{{cite journal | vauthors = Leung K | title = R-2-[131I]Iodophenyl-(1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl)methanone | journal = Molecular Imaging and Contrast Agent Database (MICAD) [Internet] | date = Dec 12, 2006 | pmid = 20641836 }}</ref><ref>{{cite journal | vauthors = Pei Y, Mercier RW, Anday JK, Thakur GA, Zvonok AM, Hurst D, Reggio PH, Janero DR, Makriyannis A | display-authors = 6 | title = Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation | journal = Chemistry & Biology | volume = 15 | issue = 11 | pages = 1207–1219 | date = November 2008 | pmid = 19022181 | pmc = 3700404 | doi = 10.1016/j.chembiol.2008.10.011 }} |
|||
</ref> AM-2233 was found to fully substitute for [[tetrahydrocannabinol|THC]] in rats, with a potency lower than that of [[JWH-018]] but higher than [[WIN 55,212-2]].<ref name="pmid21836461">{{cite journal | vauthors = Järbe TU, Deng H, Vadivel SK, Makriyannis A | title = Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats | journal = Behavioural Pharmacology | volume = 22 | issue = 5–6 | pages = 498–507 | date = September 2011 | pmid = 21836461 | pmc = 3212432 | doi = 10.1097/FBP.0b013e328349fbd5 }}</ref> |
|||
It is notable for inducing [[tinnitus]],<ref>{{cite web | url=http://hamiltonmorris.blogspot.com/2014/09/am-2233-induced-tinnitus-collected.html | title=AM-2233 INDUCED TINNITUS: COLLECTED REPORTS | date=30 September 2014 | language=en | access-date=5 April 2019}}</ref> though the reasons for this are unclear and may provide valuable insight into tinnitus research. |
|||
⚫ | |||
==Legal Status== |
|||
As of October 2015 AM-2233 is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=zh | access-date=1 October 2015 | archive-url=https://web.archive.org/web/20151001222554/http://www.sfda.gov.cn/WS01/CL0056/130753.html | archive-date=1 October 2015 | url-status=dead }}</ref> |
|||
⚫ | |||
* [[AM-679 (cannabinoid)|AM-679]] |
* [[AM-679 (cannabinoid)|AM-679]] |
||
* [[AM-694]] |
* [[AM-694]] |
||
* [[AM-1220]] |
* [[AM-1220]] |
||
* [[AM-1221]] |
* [[AM-1221]] |
||
* [[AM-1235]] |
|||
* [[AM-1241]] |
* [[AM-1241]] |
||
* [[AM-2232]] |
|||
* [[Cannabipiperidiethanone]] |
* [[Cannabipiperidiethanone]] |
||
* [[FUBIMINA]] |
|||
* [[JWH-018]] |
|||
* [[List of AM cannabinoids]] |
|||
* [[List of JWH cannabinoids]] |
|||
* [[List of HU cannabinoids]] |
|||
* [[List of designer drugs]] |
|||
==References== |
== References == |
||
{{reflist}} |
|||
<references/> |
|||
{{Cannabinoids}} |
{{Cannabinoids}} |
||
⚫ | |||
[[Category:Benzoylindoles]] |
[[Category:Benzoylindoles]] |
||
[[Category:AM cannabinoids]] |
[[Category:AM cannabinoids]] |
||
[[Category:Aminoalkylindoles]] |
[[Category:Aminoalkylindoles]] |
||
[[Category: |
[[Category:Iodobenzene derivatives]] |
||
[[Category:Piperidines]] |
[[Category:Piperidines]] |
||
⚫ | |||